NORCURON Drug Patent Profile

When do Norcuron patents expire, and what generic alternatives are available?

Norcuron is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in NORCURON is vecuronium bromide. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the vecuronium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norcuron

A generic version of NORCURON was approved as vecuronium bromide by MEITHEAL on August 25^th, 1999.

Summary for NORCURON

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	3
Patent Applications:	1,982
DailyMed Link:	NORCURON at DailyMed

Recent Clinical Trials for NORCURON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
China Medical University Hospital	Phase 4
RenJi Hospital	Phase 4
Tongji Hospital	Phase 4

See all NORCURON clinical trials

US Patents and Regulatory Information for NORCURON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984		DISCN	Yes	No
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992		DISCN	Yes	No

Expired US Patents for NORCURON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984

International Patents for NORCURON

See the table below for patents covering NORCURON around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	1593142
Ireland	791593
Philippines	16041	IMPROVED 2BETA,16BETA-BIS-PIPERIDINO ANDROSTANES
Austria	921
South Africa	7904371
Greece	72520
Belgium	676708

Market Dynamics and Financial Trajectory for NORCURON (Vecuronium Bromide)

Last updated: July 29, 2025

---

Introduction

NORCURON (Vecuronium Bromide), a neuromuscular blocking agent, plays an essential role in anesthesia during surgical procedures and intensive care units globally. Its market trajectory hinges upon factors such as technological advancements, regulatory environments, competitive landscape, and demographic shifts. This report analyses the driving market dynamics and projects the financial outlook for NORCURON over the foreseeable future.

---

Market Overview and Positioning

NORCURON, a proprietary formulation of vecuronium bromide, benefits from its rapid onset, intermediate duration, and high safety profile. Its clinical utility is markedly significant in procedures requiring temporary muscle paralysis, including intubation and anesthesia induction.

The global neuromuscular blocker market was valued at approximately USD 1.4 billion in 2021, with projections indicating a compound annual growth rate (CAGR) of 4-6% through 2028 [1]. NORCURON's segment specifically integrates into this expanding market, leveraging its established efficacy and safety credentials.

---

Key Market Drivers

1. Increasing Surgical Procedures and Anesthesia Need
Growth in elective and emergency surgeries globally propels demand for neuromuscular blockers. Anesthesia practices increasingly favor drugs with rapid onset and easy reversibility, characteristics inherent to NORCURON.

2. Rising Adoption in Intensive Care Units (ICUs)
Prolonged mechanical ventilation require neuromuscular blockade to facilitate patient management, augmenting product utilization. The surge in critical care cases during COVID-19 has temporarily heightened demand, with some normalization, still contributing to steady growth.

3. Advancements in Drug Formulation and Delivery
Innovations such as combination therapies and improved delivery mechanisms are enhancing clinical outcomes, favoring drugs like NORCURON over competitors.

4. Regulatory Approvals and Reimbursement Policies
Streamlined approval processes and favorable reimbursement policies in developed markets support market expansion. Ongoing regulatory approvals in emerging markets also offer growth avenues.

5. Competitive Dynamics and Market Penetration
Original formulations like NORCURON maintain a competitive edge over generics due to manufacturing quality, brand reputation, and supplier stability, fostering customer loyalty.

---

Market Challenges and Constraints

1. Competition from Generics
Post-patent expiry, generic versions have entered the market, exerting price pressures on NORCURON. Price sensitivity is heightened in cost-conscious markets, curbing margins.

2. Stringent Regulatory Environment
Regulatory hurdles in different jurisdictions demand ongoing compliance, impacting timely market access and development costs.

3. Side Effect Profiles and Safety Concerns
Although preferred for safety, adverse effects like residual paralysis and cardiovascular effects still prompt cautious prescribing, influencing market uptake.

4. Market Saturation in Mature Regions
In North America and Europe, market maturity limits growth potential, necessitating expansion into emerging markets.

---

Market Expansion Strategies

To sustain and grow market share, companies focus on:

• Geographical Penetration: Expanding into Asia-Pacific and Latin America, where aging populations and surgical volumes rise.
• Product Differentiation: Developing formulations with improved safety profiles or combination regimens.
• Strategic Partnerships: Collaborations with healthcare providers and distributors for broader reach.
• Regulatory Accelerations: Pursuing fast-track approvals and line extensions.

---

Financial Trajectory Projections

1. Revenue Growth Outlook
Assuming current market trends persist, NORCURON’s sales are expected to grow at a CAGR of approximately 3-5% over the next five years, driven by volume increases in emerging markets and incremental growth in mature regions. Key factors influencing revenue include:

• Price competition with generics leading to marginal price erosion.
• Increased unit volume owing to expanding procedural and ICU uses.
• Launch of new product forms or indications.

2. Profitability and Margin Trends
Despite competitive pressures, operational efficiencies, and economies of scale could stabilize profit margins. R&D investments for line extensions or improved formulations may initially impact margins but foster future revenue streams.

3. Investment and R&D Outlook
Ongoing investment in pipeline development indicates a strategic move to diversify and enhance offerings, aiming for long-term financial stability.

4. Risks and Uncertainties
Regulatory delays, unforeseen safety concerns, or disruptive market entrants could influence financial projections negatively. Conversely, positive market acceptance and regulatory approvals can bolster growth.

---

Regulatory and Market Outlook

Regulatory agencies such as FDA, EMA, and PMDA remain pivotal. Fast-track approvals and orphan drug designations could expedite market access for innovative formulations or indications. Additionally, global health initiatives targeting surgical safety and ICU capabilities underpin continued demand.

---

Conclusion

NORCURON’s market environment is characterized by steady growth driven by increasing global surgical volumes and ICU needs. Competitive pressures from generics and regional regulatory developments are notable constraints. Yet, strategic expansion, innovation, and market penetration in emerging economies support a cautiously optimistic financial trajectory. Sustainability hinges on adapting to evolving regulatory, competitive, and clinical landscapes.

---

Key Takeaways

• NORCURON's demand aligns with global surgical and critical care growth, with moderate expansion projected through 2028.
• Competition from generics necessitates strategic differentiation and geographical expansion.
• Regulatory pathways and reimbursement policies in emerging markets represent significant opportunities.
• Future profitability depends on managing pricing pressures, optimizing operational efficiencies, and investing in innovative line extensions.
• Market resilience will depend on compliance, safety profile optimization, and expanding into new indications and regions.

---

FAQs

Q1: How does NORCURON compare to other neuromuscular blockers in the market?
NORCURON offers a balanced profile with rapid onset and short to intermediate duration, comparable or superior to alternatives like rocuronium. Its safety profile and reversibility robustness position it favorably, especially in settings prioritizing quick recovery.

Q2: What are the primary regulatory challenges facing NORCURON?
Regulatory challenges include gaining approval in emerging markets, ensuring compliance with evolving safety standards, and managing post-marketing surveillance requirements.

Q3: How will the generic market affect NORCURON’s profitability?
Generics exert downward pressure on prices post-patent expiry, potentially reducing margins. Maintaining market share relies on branding, quality, and strategic affordability in competitive regions.

Q4: What growth opportunities exist in emerging markets?
Expanding distribution networks, establishing local manufacturing, and tailoring formulations for regional needs are pivotal to capitalize on rising surgical volumes and ICU cases.

Q5: How might technological innovations impact NORCURON's market position?
Advances like drug delivery systems, combination therapies, and biosimilars could influence market dynamics, requiring NORCURON to innovate continually and adapt its formulations.

---

Sources:

[1] Grand View Research, "Neuromuscular Blockers Market Size, Share & Trends Analysis," 2022.